Year: 2023
Type: article
Abstract: Multiple myeloma (MM) is the second most common hematological malignancy in the United States predicted to cause 34,470 new cases and 12,640 deaths in 2022 [ 1 ]. Outcomes of patients with MM continue to improve with the advent of highly effective multidrug therapy regimens and high-dose chemotherapy with autologous stem cell transplant [ 2 ]. With improvements in flow cytometry (FCM) and next-generation sequencing (NGS) technologies, attaining measurable residual disease (MRD) negativity in the bone marrow (BM) after treatment, a deeper level of response than stringent complete response (sCR), has emerged as an important prognostic factor for patients [ 3 ]. Next-generation flow cytometry (NGF) and NGS are the recommended techniques for MRD detection currently in use [ 4 ]. The accepted NGF MRD method is a 2-tube, 10-antibody (Ab) test (Euroflow Consortium) with a minimum sensitivity of 10 −5 [ 5 , 6 ]. This assay requires significant processing, instruments, and analysis time [ 6 ].
Source: Blood Cancer Journal
Authors: Vandana Panakkal, Arjun Lakshman, Min Shi, Horatiu Olteanu, Pedro Horna, Michael M. Timm, Gregory E. Otteson, Linda B. Baughn, Patricia T. Greipp, Wilson I. Gonsalves, Prashant Kapoor, Morie A. Gertz, Moritz Binder, Francis K. Buadi, Angela Dispenzieri, S. Vincent Rajkumar, Shaji K. Kumar, Dragan Jevremovic
Institution: Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,790
Funder: National Cancer Institute
Award: G686564698
OpenAlex ID: W4366598889